Lifeward Ltd. Reports Q2 2026 Revenue Growth but Increased Net Loss

Lifeward Ltd. reported its financial results for the second quarter of 2026, revealing revenues of $6.6 million, a 15.7% increase from $5.7 million in the same period last year. However, the company experienced a net loss of $11.5 million, compared to a loss of $6.6 million in the prior year. For the first half of 2026, revenues totaled $10.5 million, slightly down from $10.8 million in the first half of 2025. The company's gross profit for the quarter was $2.7 million, up from $2.5 million year-over-year, but operating expenses also increased, leading to a larger operating loss of $4.2 million compared to $6.6 million in the previous year.

Significant changes in the company's financial position include a notable increase in total assets, which rose to $35 million as of June 30, 2026, from $22.9 million at the end of 2025. This increase was primarily driven by cash and cash equivalents, which grew to $9.4 million from $2.2 million, and the addition of clinical trial service assets related to the acquisition of Oratech Pharmaceuticals. Lifeward's total liabilities also increased to $22.8 million, up from $14.5 million, largely due to the issuance of convertible promissory notes and other financing liabilities.

Strategically, Lifeward has made several key acquisitions to expand its product offerings and market presence. In August 2023, the company acquired AlterG, Inc., a provider of anti-gravity rehabilitation systems, and in March 2026, it acquired Oratech, which focuses on innovative pharmaceutical technologies. Additionally, in May 2026, Lifeward acquired intellectual property from Skelable Ltd. to support the development of a powered upper-body robotic exoskeleton. These acquisitions are expected to enhance Lifeward's capabilities in the rehabilitation sector and broaden its product portfolio.

Operationally, Lifeward has seen a shift in its manufacturing strategy, transitioning the production of its ReWalk exoskeleton products to its facility in Yokneam, Israel. The company reported a significant increase in its employee headcount, reflecting its growth and expansion efforts. As of June 30, 2026, Lifeward had 2,828,362 outstanding shares following a reverse stock split, which was effective on February 24, 2026. The company continues to market its products primarily in the United States, with distribution channels established in Germany, Canada, and Australia.

Looking ahead, Lifeward anticipates ongoing operating losses and negative cash flows, raising concerns about its ability to continue as a going concern without additional funding. The company plans to seek further capital to support its operations and may implement cost-saving measures if necessary. Management has expressed confidence in the potential of its recent acquisitions and product developments to drive future growth, but acknowledges the need for careful financial management in the coming months.